Published in Drug Week, February 16th, 2007
The new Pharmacor report Outlook for Antidepressants, 2006-2016: Will Novel Agents Surprise the Market' finds that the melatonin agonist Valdoxan/Thymanax will experience rapid uptake as a first-line treatment in the primary care setting, following its launch in 2010. The report finds that, unlike other later-stage novel antidepressants, melatonin agonists do not have a history of tolerability issues and physicians have indicated acceptance of this class in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.